Celularity Inc.

As of December 31, 2025, Celularity Inc. carries a market capitalization of 32.01M, placing it among publicly traded companies globally. Its enterprise value stands at 66.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Celularity Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of December 31, 2025, Celularity Inc. has 28.84M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 1.07, and the price-to-book ratio stands at -0.84.

These figures are as of December 31, 2025. The EV/Sales ratio of 2.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 66.74M versus a market cap of 32.01M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Celularity Inc. maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -107.46, indicating conservative leverage, while an interest coverage ratio of -8.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -76.43, reflecting losses generated across the asset base. The company generates approximately 219,421.49 in revenue per employee across its workforce of 121.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.71 indicates how many times Celularity Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Celularity Inc. recorded 3,000.00 in income tax expense. The company reported a pretax loss of -91.71M and -91.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Celularity Inc.'s stock has declined approximately 47.66% over the past 52 weeks. The 50-day moving average sits at 1.30, while the 200-day moving average is 1.10.

Over the twelve months ended December 31, 2025, Celularity Inc. generated 26.55M in revenue and converted that into -91.72M in net income, yielding earnings per share of -3.57. EBITDA reached -54.01M, while operating income came in at -61.31M.

As of December 31, 2025, Celularity Inc. holds 6.18M in cash and equivalents against 40.90M in total debt, resulting in a net debt position of 7.83M. Total book value stands at -38.06M, with working capital of -68.44M providing operational flexibility.

Celularity Inc. produced -13.25M in operating cash flow over the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Celularity Inc. posted a gross margin of 24.39, reflecting its pricing power and cost economics. The operating margin of -230.92 and net profit margin of -345.45 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Celularity Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -46.49: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -58.26, meaning Celularity Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Celularity Inc.'s most recent stock split took place on February 29, 2024 with a 10:1 split ratio.

As of December 31, 2025, Celularity Inc. has an Altman Z-Score of -17.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.